Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6055147 | 0.90 | GRIA4 (0.45) | LMNAKCNH2MEN1MAPTKMT2A | |
| SCHEMBL6827541 | 0.85 | LMNA (0.46) | LMNAKCNH2MEN1MAPTKMT2A | |
| SCHEMBL28691397 | 0.83 | HSD11B1 (0.46) | LMNAKCNH2MEN1KMT2ACACNA1F | |
| SCHEMBL8418135 | 0.83 | LMNA (0.45) | LMNAKCNH2MEN1MAPTKMT2A | |
| SCHEMBL17023787 | 0.83 | LMNA (0.45) | LMNAKCNH2MEN1MAPTKMT2A | |
| SCHEMBL24298369 | 0.83 | LMNA (0.45) | LMNAKCNH2MEN1MAPTKMT2A | |
| SCHEMBL8418142 | 0.83 | LMNA (0.45) | LMNAKCNH2MEN1MAPTKMT2A | |
| SCHEMBL3187891 | 0.82 | LMNA (0.45) | LMNAKCNH2MEN1MAPTKMT2A | |
| SCHEMBL6055239 | 0.82 | LMNA (0.56) | LMNAKCNH2MEN1MAPTKMT2A | |
| SCHEMBL20748168 | 0.81 | GRIA4 (0.47) | LMNARIPK1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858798-B2 | metabolite of ebastine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090137813-A1 | PROCESS FOR PRODUCTION OF CAREBASTINE | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1300381-B1 | Process for preparing optically active alcohols | JAPAN SCIENCE & TECH AGENCY (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-6887820-B1 | For producing optically active secondary alcohols, producing optically active compounds useful for various utilities such as intermediates for synthesizing pharmaceutical agents, liquid crystal materials and agents for optical resolution | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-05-03 | — | — | US | disclosed |
| EP-1300381-A1 | Process for preparing optically active alcohols | Japan Science and Technology Corporation (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6184381-B1 | USEFUL AS INTERMEDIATES FOR SYNTHESIZING PHARMACEUTICAL CHEMICALS, LIQUID CRYSTAL MATERIALS AND AGENTS FOR OPTICAL RESOLUTION, REDUCTION, KETONES TO ALCOHOL, IMINES TO AMINES | JAPAN SCIENCE & TECHNOLOGY CORP. (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0916637-A1 | PROCESS FOR PREPARATING OPTICALLY ACTIVE COMPOUNDS | Japan Science and Technology Corporation (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137813-A1 | PROCESS FOR PRODUCTION OF CAREBASTINE | GABRE, GABRB3, GABRB2 | LMNA 3783/4885KCNH2 1006/4885MEN1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.